Gilead on Sunday agreed to buy the biopharmaceutical company for $21 billion and acquire all the outstanding shares of Immunomedics for $88 per share, at a premium of about 108% over Friday's closing price of $42.25.
The deal gives Gilead access to Immunomedics' cancer treatment drug, Trodelvy, which was granted an accelerated approval in April by the U.S. Food and Drug administration for an aggressive and tough-to-treat type of breast cancer.
Brokerage Jefferies said investors may take some time to digest the deal, but it believed the deal offered a path for Gilead to quickly move into the solid tumors market.
Brokerage Oppenheimer views the purchase price as "reasonable", and said the cancer drug "slots neatly" in Gilead's oncology strategy.
Earlier in the day, at least two brokerages raised concerns about the deal price.
Baird said Trodelvy should give Gilead a "nice addition" to cement its foothold in the cancer treatment sphere, but that it was "less than thrilled" about the price.
SVB Leerink expected the main push back from investors to be about the deal price, not the product or the commercial opportunity.
"Gilead's purchase price is at a 300% premium to where Immunomedics traded at the start of the year, and more than 100% higher than where the stock had recently traded," the brokerage said.
Gilead's shares rose 3.3% to $67 in morning trading, after falling as much as 2% before the opening bell on Monday.
(Reporting by Vishwadha Chander in Bengaluru; Editing by Shinjini Ganguli)